<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1050">
  <stage>Registered</stage>
  <submitdate>1/02/2006</submitdate>
  <approvaldate>1/02/2006</approvaldate>
  <nctid>NCT00286429</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.</studytitle>
    <scientifictitle>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Insulin in Subjects With Type 2 Diabetes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2005-004671-38</secondaryid>
    <secondaryid>SYR-322-INS-011</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Alogliptin and insulin
Treatment: drugs - Alogliptin and insulin
Treatment: drugs - Insulin

Placebo Comparator: Insulin - 

Experimental: Alogliptin 12.5 mg QD - 

Experimental: Alogliptin 25 mg QD - 


Treatment: drugs: Alogliptin and insulin
Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.

Treatment: drugs: Alogliptin and insulin
Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.

Treatment: drugs: Insulin
Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26. - The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline.</outcome>
      <timepoint>Baseline and Week 26.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Glycosylated Hemoglobin (Week 4). - The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and Glycosylated Hemoglobin collected at baseline.</outcome>
      <timepoint>Baseline and Week 4.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Glycosylated Hemoglobin (Week 8). - The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and Glycosylated Hemoglobin collected at baseline.</outcome>
      <timepoint>Baseline and Week 8.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Glycosylated Hemoglobin (Week 12). - The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and Glycosylated Hemoglobin collected at baseline.</outcome>
      <timepoint>Baseline and Week 12.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Glycosylated Hemoglobin (Week 16). - The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and Glycosylated Hemoglobin collected at baseline.</outcome>
      <timepoint>Baseline and Week 16.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Glycosylated Hemoglobin (Week 20). - The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and Glycosylated Hemoglobin collected at baseline.</outcome>
      <timepoint>Baseline and Week 20.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Fasting Plasma Glucose (Week 1). - The change between the value of fasting plasma glucose collected at final visit or week 1 and fasting plasma glucose collected at baseline.</outcome>
      <timepoint>Baseline and Week 1.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Fasting Plasma Glucose (Week 2). - The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline.</outcome>
      <timepoint>Baseline and Week 2.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Fasting Plasma Glucose (Week 4). - The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline.</outcome>
      <timepoint>Baseline and Week 4.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Fasting Plasma Glucose (Week 8). - The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline.</outcome>
      <timepoint>Baseline and Week 8.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Fasting Plasma Glucose (Week 12). - The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline.</outcome>
      <timepoint>Baseline and Week 12.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Fasting Plasma Glucose (Week 16). - The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline.</outcome>
      <timepoint>Baseline and Week 16.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Fasting Plasma Glucose (Week 20). - The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline.</outcome>
      <timepoint>Baseline and Week 20.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Fasting Plasma Glucose (Week 26). - The change between the value of fasting plasma glucose collected at week 26 or final visit and fasting plasma glucose collected at baseline.</outcome>
      <timepoint>Baseline and Week 26.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose = 200 mg Per dL). - The number of participants with a fasting plasma glucose value greater than or equal to 200 mg per dL during the 26 week study.</outcome>
      <timepoint>26 Weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants Requiring Rescue. - The number of participants requiring rescue for failing to achieve pre-specified glycemic targets during the 26 week study.</outcome>
      <timepoint>26 Weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in C-peptide (Week 4). - The change between the value of C-peptide collected at week 4 and C-peptide collected at baseline.</outcome>
      <timepoint>Baseline and Week 4.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in C-peptide (Week 8). - The change between the value of C-peptide collected at week 8 and C-peptide collected at baseline.</outcome>
      <timepoint>Baseline and Week 8.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in C-peptide (Week 12). - The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline.</outcome>
      <timepoint>Baseline and Week 12.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in C-peptide (Week 16). - The change between the value of C-peptide collected at week 16 and C-peptide collected at baseline.</outcome>
      <timepoint>Baseline and Week 16.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in C-peptide (Week 20). - The change between the value of C-peptide collected at week 20 and C-peptide collected at baseline.</outcome>
      <timepoint>Baseline and Week 20.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in C-peptide (Week 26). - The change between the value of C-peptide collected at week 26 or final visit and C-peptide collected at baseline.</outcome>
      <timepoint>Baseline and Week 26.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Glycosylated Hemoglobin = 6.5%. - The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 6.5% during the 26 week study.</outcome>
      <timepoint>Baseline and Week 26.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Glycosylated Hemoglobin = 7.0%. - The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.0% during the 26 week study.</outcome>
      <timepoint>Baseline and Week 26.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Glycosylated Hemoglobin = 7.5%. - The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.5% during the 26 week study.</outcome>
      <timepoint>Baseline and Week 26.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Glycosylated Hemoglobin Decrease From Baseline = 0.5%. - The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 0.5% during the 26 week study.</outcome>
      <timepoint>Baseline and Week 26.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Glycosylated Hemoglobin Decrease From Baseline = 1.0%. - The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.0% during the 26 week study.</outcome>
      <timepoint>Baseline and Week 26.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Glycosylated Hemoglobin Decrease From Baseline = 1.5%. - The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.5% during the 26 week study.</outcome>
      <timepoint>Baseline and Week 26.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Glycosylated Hemoglobin Decrease From Baseline = 2.0%. - The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 2.0% during the 26 week study.</outcome>
      <timepoint>Baseline and Week 26.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Body Weight (Week 8). - The change between Body Weight measured at week 8 and Body Weight measured at baseline.</outcome>
      <timepoint>Baseline and Week 8.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Body Weight (Week 12). - The change between Body Weight measured at week 12 and Body Weight measured at baseline.</outcome>
      <timepoint>Baseline and Week 12.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Body Weight (Week 20). - The change between Body Weight measured at week 20 and Body Weight measured at baseline.</outcome>
      <timepoint>Baseline and Week 20.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Body Weight (Week 26). - The change between Body Weight measured at week 26 or final visit and Body Weight measured at baseline.</outcome>
      <timepoint>Baseline and Week 26.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          -  Diagnosis of type 2 diabetes mellitus and currently treated with insulin alone (with
             or without metformin), and is inadequately controlled. Metformin dose must be stable
             for at least 8 weeks prior to Randomization.

          -  No treatment with antidiabetic agents other than insulin and metformin within the 8
             weeks prior to Randomization.

          -  Body mass index greater than or equal to 23 kg/m2 and less than or equal to 45 kg/m2

          -  Fasting C-peptide concentration greater than or equal to 0.8 ng per mL. (If this
             screening criterion is not met, the subject still qualifies if C-peptide greater than
             or equal to 1.5 ng per mL after a challenge test).

          -  Glycosylated hemoglobin concentration greater than or equal to 8.0% at Screening.

          -  Using a stable dose of insulin of at least 15 units but not more than 100 units per
             day for at least 8 weeks prior to Randomization. A dose of insulin that varies by up
             to 15% of the mean will be considered as stable.

          -  If regular use of other, non-excluded medications, must be on a stable dose for at
             least the 4 weeks prior to Screening. However, as needed use of prescription or
             over-the-counter medications is allowed at the discretion of the investigator.

          -  Systolic blood pressure less than or equal to180 mm Hg and diastolic pressure less
             than or equal to 110 mm Hg

          -  Hemoglobin greater than or equal to 12 g per dL for males and greater than or equal
             to10 g per dL for females.

          -  Alanine aminotransferase less than or equal to 3 times the upper limit of normal.

          -  Serum creatinine less than or equal to 2.0 mg per dL.

          -  Thyroid-stimulating hormone level less than or equal to the upper limit of the normal
             range and the subject is clinically euthyroid.

          -  Neither pregnant (confirmed by laboratory testing in females of childbearing
             potential) nor lactating.

          -  Female subjects of childbearing potential must be practicing adequate contraception.
             Adequate contraception must be practiced for the duration of participation in the
             study.

          -  Able and willing to monitor own blood glucose concentrations with a home glucose
             monitor

          -  No major illness or debility that in the investigator's opinion prohibits the
             individual from completing the study

          -  Able and willing to provide written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          -  Urine albumin to creatinine ratio of greater than 1000 µg per mg at Screening. If
             elevated, the subject may be rescreened within 1 week.

          -  History of cancer, other than squamous cell or basal cell carcinoma of the skin, that
             has not been in full remission for at least 5 years prior to Screening. (History of
             treated cervical intraepithelial neoplasia I or cervical intraepithelial neoplasia II
             is allowed.).

          -  History of laser treatment for proliferative diabetic retinopathy within the 6 months
             prior to Screening.

          -  History of treated diabetic gastric paresis.

          -  New York Heart Association Class III or IV heart failure regardless of therapy.
             Currently treated subjects who are stable at Class I or II are candidates for the
             study.

          -  History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or
             myocardial infarction within the 6 months prior to Screening.

          -  History of any hemoglobinopathy that may affect determination of glycosylated
             hemoglobin.

          -  History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.

          -  History of a psychiatric disorder that will affect ability to participate in the
             study.

          -  History of angioedema in association with use of angiotensin-converting enzyme
             inhibitors or angiotensin-II receptor inhibitors.

          -  History of alcohol or substance abuse within the 2 years prior to Screening.

          -  Receipt of any investigational drug within the 30 days prior to Screening or a history
             of receipt of an investigational antidiabetic drug within the 3 months prior to
             Screening.

          -  Prior treatment in an investigational study of alogliptin.

          -  Excluded Medications:

               -  Treatment with antidiabetic agents other than insulin and metformin is not
                  allowed within the 8 weeks prior to Randomization and through the completion of
                  the end-of treatment or early termination procedures. (Exception: if has received
                  other antidiabetic therapy for less than 7 days within the 3 months prior to
                  Screening.)

               -  Treatment with weight-loss drugs, any investigational antidiabetics, or oral or
                  systemically injected glucocorticoids is not allowed from 3 months prior to
                  randomization through the completion of the end-of-treatment or early termination
                  procedures. Inhaled corticosteroids are allowed.

               -  Must not take any medications, including over-the-counter products, without first
                  consulting with the investigator.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>390</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Multiple Cities</hospital>
    <postcode> - Multiple Cities</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Vermont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Guatemala</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Multiple Cities</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Takeda</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the efficacy and safety of alogliptin, once daily
      (QD), taken in combination with insulin for the treatment of Type 2 Diabetes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00286429</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>VP Biological Sciences</name>
      <address>Takeda</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>